Patents by Inventor George Edwin Katibah

George Edwin Katibah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazine Compounds and Uses Thereof
    Publication number: 20210246122
    Abstract: The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 12, 2021
    Applicant: Aduro Biotech, Inc.
    Inventors: George Edwin Katibah, Jung Yun Kim, Chudi Obioma Ndubaku, Meiliana Tjandra, Tucker Curran Roberts
  • Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
    Patent number: 11040053
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: June 22, 2021
    Assignee: CHINOOK THERAPEUTICS, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10906930
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 2, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku
  • Pyrazolopyrimidinone compounds and uses thereof
    Patent number: 10738056
    Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: August 11, 2020
    Assignee: Aduro BioTech Inc.
    Inventors: Chudi Obioma Ndubaku, George Edwin Katibah, Tucker Curran Roberts, Leonard Sung, Stephane Ciblat, Franck Raeppel, Vu Linh Ly, Yeeman K. Ramtohul, Taras Rybak, Mariam Zaky, Laura Gillard, Hossein Ismaili
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING
    Publication number: 20200179431
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Application
    Filed: October 21, 2019
    Publication date: June 11, 2020
    Applicant: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, JR.
  • Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
    Patent number: 10449211
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: October 22, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF
    Publication number: 20190119285
    Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 25, 2019
    Inventors: Chudi Obioma NDUBAKU, George Edwin KATIBAH, Tucker Curran ROBERTS, Leonard SUNG, Stephane CIBLAT, Franck RAEPPEL, Vu Linh LY, Yeeman K. RAMTOHUL, Taras RYBAK, Mariam ZAKY, Laura GILLARD, Hossein ISMAILI
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20190062365
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 28, 2019
    Applicants: ADURO BIOTECH, INC., NOVARTIS AG
    Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Kelsey GAUTHIER, Laura Hix GLICKMAN, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, Jr., Jeffrey McKENNA, Stephen M. CANHAM, Chudi Obioma NDUBAKU
  • METHODS FOR IDENTIFYING INHIBITORS OF "STIMULATOR OF INTERFERON GENE"- DEPENDENT INTERFERON PRODUCTION
    Publication number: 20180369268
    Abstract: The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 27, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, JR.
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING
    Publication number: 20180064745
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 8, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.